Clin2
NCT07691970Possibly a fitNot yet recruiting

Continuation study for anifrolumab beneficiaries

Systemic Sclerosis Cutaneous Lupus E Myopathies Systemic Lupus Erythematosus

Treatments studied

Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.

This trial lets people who completed a prior anifrolumab study and saw benefit continue receiving the drug. It monitors long-term safety and effectiveness.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
1,072 people
Ages
5 years to 80 years
Study type
Interventional

Who can take part

  • You finished a previous anifrolumab study and received at least one dose
  • Your doctor believes continuing anifrolumab is safe and beneficial for you
  • You agree to follow contraception rules for 16 weeks after the last dose
  • You are not pregnant, breastfeeding, or planning pregnancy
  • You have no serious side effects from the previous study that would stop treatment
  • You did not stop the parent study early

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07330245Recruiting
Study of anifrolumab for lupus patients needing treatment

This study looks at how well anifrolumab works for people with systemic lupus erythematosus (SLE) who are starting it for the first time. It aims to see if patients can achieve a low disease activity state (LLDAS5) after treatment.

Monserrato, CA
NCT07430306Recruiting· Phase 3
Study of anifrolumab for lupus patients not yet on strong treatments

This trial tests if a new drug called anifrolumab can help treat lupus in people who haven't taken strong medications like biologics or immunosuppressants before. It looks at overall disease activity and the chance to reduce steroid use.

Anniston, Alabama
NCT06314282Recruiting
Lupus study tracking real-world results with anifrolumab

This study looks at how well anifrolumab works for people with lupus in everyday medical care, not just in a research lab. It may help you if your doctor has decided to prescribe anifrolumab for the first time.

Buenos Aires
NCT07215754Recruiting
Real-world study of anifrolumab for active lupus

This study tracks how well anifrolumab works and how safe it is for people with active lupus. It's a real-world look at the drug's effects, so no additional treatments or tests are required beyond what your doctor already prescribes.

Pisa
NCT07751848Not yet recruiting· Phase 3
Study of anifrolumab for Chinese patients with active lupus

This trial tests anifrolumab, an investigational drug that may help reduce lupus activity in people with moderate-to-severe disease. If you have active lupus despite current treatments, this study might offer a new option.

Beijing
NCT07688980Not yet recruiting· Phase 1
Study of anifrolumab for lupus

This trial tests anifrolumab, given as a shot under the skin or through a vein, to see how it works in people with lupus. It may help if you have active lupus symptoms and are on standard treatments.

Hear when a new Systemic Sclerosis Cutaneous Lupus E Myopathies Systemic Lupus Erythematosus trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.